NEXGEL, INC.
NXGLAbout the company
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions.
Investment snapshot
Positive
2
BUY / PASS
Neutral / negative
1 / 13
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 16 investors flag at least one profitability criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #2892 (Top 93.4%) | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025 Latest source filing: 2026-08-17 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30 Latest source filing: 2026-08-17 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-17 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-17 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30 Latest source filing: 2026-08-17 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-17 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-17 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-31 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-08-17 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-17 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-08-17 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Profitability0% pass✓ 5✗ 30▾
No clean pass — all 16 investors flag at least one profitability criterion
Positive EPS (10 years)0/9 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthNet Income Positive (10+ years)0/9 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-57.9%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-29.3% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-2.6M✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-125.0%✗Lynch> 15%EBIT / Enterprise Value-142.6%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-142.6%, ROC=-111.0%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-28.68%✗PiotroskiROA > 0ROA Change YoY-29.87% -> -28.68% (delta: +1.20%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-12.53%, ROA=-28.68%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY31.6% -> 39.5%✓PiotroskiImproved YoYPre-Tax Income / Revenue-50.2%✗Dreman>= 8%Net Income / Shareholders' Equity-125.0%✗Dreman> 12%Margin of SafetyP/B=7.1x✗PabraiP/B < 1.5 or P/E < 15Return on Equity-63.8% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/8 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-44.8%✗Ackman>= 15%Net Income / Shareholders Equity-125.0%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-85.0% (2023) -> -29.3% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 9.1% -> 39.5%, operating margin -85.0% -> -29.3%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-297.34%; #5788/6340 (top 91.3%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+16.00%; #2362/3702 (top 63.8%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-124.97%; #4693/5226 (top 89.8%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.0707; #3039/5884 (top 51.6%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/8 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Valuation0% pass✓ 4✗ 24▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio7.1x✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-142.6%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-142.6%, ROC=-111.0%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share7.1x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-8.3%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-66.3%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=7.1x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low2180% of trailing low ($0.18)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-297.34%; #5788/6340 (top 91.3%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+2.3792; #578/6449 (top 9.0%)✓AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share11.92x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change+76508.1%✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+5.8006; #481/5247 (top 9.2%)✓OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-66.29%; #3942/4519 (top 87.2%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date+546.67%; #76/6202 (top 1.2%)✓OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy$-2.6M✗BuffettPositive and growingFCF Positive and Growing$-1.4M✗LynchPositive and growingOperating Cash Flow$-1.3M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-12.53%, ROA=-28.68%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-66.3%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/7 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-4.4%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/8 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-1.4M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-66.29%; #3942/4519 (top 87.2%)✗OshaughnessyTop 10% of eligible cross-section - Efficiency0% pass✓ 1✗ 10▾
No clean pass — all 8 investors flag at least one efficiency criterion
Current Ratio0.43✗Graham>= 2.0ROIC (3-5 yr avg)-90.1%✗Buffett> 10%ROIC - WACC-100.1%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-111.0%✗Greenblatt> 25%Current Ratio Change YoY2.07 -> 1.47✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.79x -> 1.09x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities0.43✗Dreman> 1.5Return on Invested Capital-52.7%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-50.4%; FY2024: ROIC=-43.6%; FY2025: ROIC=-52.5%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/5 years above 12% (latest -52.5%)✗SleepROIC > 12% in a majority of years - Growth13% pass✓ 3✗ 10▾
7 of 8 flag NXGL's growth — Graham, Lynch, Dreman +4 more
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: 26.5% vs Rev: 3.4%✗LynchInventory growth < Revenue growthEPS Growth Direction$-0.38 (2018) -> $-0.38 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/8 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth99.7%✓Ackman>= 5%Positive EPS Growth Frequency4/5 years with positive EPS growth✓AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 9.1% -> 39.5%, operating margin -85.0% -> -29.3%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR76.1%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Verdicts13% pass✓ 2✗ 14▾
Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL
Overall verdict✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)✗GreenblattRank #2892✓PiotroskiPASS (F-Score 5)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✓AckmanPASS (4/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1400/2370 (Top 59.1%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage33% pass✓ 6✗ 9▾
8 of 12 flag NXGL's debt & leverage — Buffett, Lynch, Dreman +5 more
LT Debt vs Net Current AssetsLT Debt $0.6M vs NCA $1.4M✓GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.13, IC: -98.6x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0.64✗Lynch< 0.33Cash - Long-term Debt$-0.3M✗LynchPositive preferredLT Debt / Total Assets Change6.24% -> 5.62%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities0.43✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0.64✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xDebt Levels0.64✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-98.6x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.64✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.6377; #2729/4210 (top 64.8%)✗AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 6.4% of shares last year, 41.8% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-06-30 2025-07-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex, revenue, net income, operating income, gross profit, ebit, pre tax income. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.1Mcurrent | -- | -- | $11.6Mest. | $29.2Mest. | $12.6Mest. | $7.9Mest. | $14.8Mest. |
| Revenue | $12.1M↑3% | $3.7M↑28% | $2.6M↓6% | $11.4M↑31% | $8.7M↑112% | $4.1M↑100% | $2.0M↑32% | $1.6M |
| Operating Income | -$5.4M↓78% | -$2.5M↓294% | -$958.0K↓23% | -$3.4M↑6% | -$3.6M↓2% | -$3.5M↓4% | -$3.3M↓30% | -$2.6M |
| Net Income | -$6.2M↓112% | -$3.6M↓447% | -$927.0K↓30% | -$3.0M↑9% | -$3.3M↓4% | -$3.2M↑33% | -$4.7M↓10% | -$4.3M |
| EPS (Diluted) | -- | $-0.40↓344% | $-0.11↓22% | $-0.38↑24% | $-0.50↑11% | $-0.56↑34% | $-0.85↑41% | $-1.45 |
| Gross Margin | 35.1%↓9% | 30.1%↓31% | 40.0%↓5% | 39.5%↑25% | 31.6%↑246% | 9.1%↓27% | 12.5%↑2323% | 0.5% |
| Operating Margin | -44.8%↓72% | -68.0%↓208% | -36.2%↓31% | -29.3%↑28% | -40.9%↑52% | -85.0%↑48% | -163.5%↑1% | -165.7% |
| ROE | -125.0%↓100% | — | — | -67.3%↓18% | -57.0%↑15% | -67.2%↓8% | -62.1%↓74% | -35.7% |
| Total Debt | $3.2M↑395% | $3.2M↑395% | $563.0K↓15% | $588.0K↓14% | $685.0K↓10% | $758.0K↑168% | $283.0K↓88% | $2.3M |
| Shareholders' Equity | $4.9M↑6% | $4.9M↑6% | $4.0M↓23% | $4.5M↓23% | $5.8M↑23% | $4.7M↓38% | $7.6M↓37% | $12.1M |
| Current Ratio | 0.43↓75% | 0.43↓75% | 1.70↓10% | 1.47↓29% | 2.07↑4% | 1.98↓77% | 8.74↑81% | 4.82 |
| Debt / Equity | 0.64↑367% | 0.64↑367% | 0.14↑11% | 0.13↑11% | 0.12↓26% | 0.16↑335% | 0.04↓81% | 0.19 |
| Operating Cash Flow | -$3.2M↓11% | -$2.2M↓440% | -$504.0K↓26% | -$1.3M↑66% | -$3.9M↓19% | -$3.2M↓8% | -$3.0M↓9% | -$2.8M |
| Free Cash Flow | -- | -- | -$513.0K | -$1.4M↑68% | -$4.3M↓10% | -$3.9M↓27% | -$3.1M↓2% | -$3.0M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Medical Equipment
NXGL vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALCON INCALC | $35.6B | $74.12 | $10.4B | $980.0M | 4.4% | 0.21 | 13.1% | 2.12 | 2/9 | 1/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| KONINKLIJKE PHILIPS NVPHG | $29.7B | $30.34 | $21.0B | $1.1B | 8.2% | 0.64 | 8.0% | 1.32 | 1/9 | 1/9 | 1/7 | 0/3 | F-Score 5 | 3/11 |
| WEST PHARMACEUTICAL SERVICES INCWST | $29.0B | $416.42 | $3.1B | $493.7M | 15.5% | 0.06 | 19.0% | 3.02 | 4/9 | 6/9 | 6/7 | 1/3 | F-Score 7 | 5/11 |
| SMITH & NEPHEW PLCSNN | $13.1B | $31.28 | $6.2B | $625.0M | 11.8% | 0.59 | 12.9% | 2.57 | 2/9 | 0/9 | 1/7 | 0/3 | F-Score 6 | 4/11 |
| MSA Safety IncMSA | $6.7B | $174.17 | $1.9B | $278.9M | 20.4% | 0.42 | 19.8% | 3.01 | 5/9 | 5/9 | 4/7 | 1/3 | F-Score 5 | 7/11 |
| STAAR SURGICAL COSTAA | $1.3B | $26.39 | $239.4M | $80.4M | -23.4% | — | -38.3% | 4.55 | 2/9 | 2/9 | 2/7 | 0/3 | F-Score 3 | 3/11 |
| ARTIVION, INC.AORT | $931.9M | $19.10 | $441.3M | $9.8M | 2.2% | 0.48 | 7.6% | 3.53 | 2/9 | 0/9 | 0/7 | 0/3 | F-Score 7 | 1/11 |
| InMode Ltd.INMD | $763.6M | $13.27 | $370.5M | $93.8M | 13.7% | — | 23.0% | 9.88 | 5/9 | 3/9 | 0/7 | 3/3 | F-Score 4 | 4/11 |